Imidazole-2-thiones
    22.
    发明授权
    Imidazole-2-thiones 有权
    咪唑-2-硫酮

    公开(公告)号:US07960423B2

    公开(公告)日:2011-06-14

    申请号:US11873537

    申请日:2007-10-17

    IPC分类号: A61K31/4164 C07D233/30

    摘要: Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

    摘要翻译: 式1的化合物,其中X为S且变量具有本说明书中定义的含义,优先于α2B肾上腺素能受体,对α2B和/或α2C肾上腺素能受体是特异性或选择性的,因此没有或仅有最小的血管内和/或镇静 活动。 式1的这些化合物可用作哺乳动物(包括人)中用于治疗疾病的药物和/或缓解对α2B肾上腺素能受体的激动剂治疗有反应的病症。 其中X是O的式1化合物也具有它们没有或只有最小的血管内和/或镇静作用的有利性质,并且可用于治疗没有或仅有最小血管和/或镇静作用的疼痛和其它病症。